Anrukinzumab, CAS 910649-32-0

Product Description: Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma[1][2][3].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Reinisch W, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 2015 Jun;64(6):894-900. /[2]Elias JA, et al. IL-13 in asthma. The successful integration of lessons from mice and humans. Am J Respir Crit Care Med. 2011 Apr 15;183(8):957-8. /[3]Bree A, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol. 2007 May;119(5):1251-7.

CAS Number: 910649-32-0

Molecular Weight: N/A

Compound Purity: 98.64

Research Area: Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: Interleukin Related

• Artikelnummer: MEXHY-P99439-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99439-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK